PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer
Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Yong Wha Moon, Masa-Aki Shibata, Sasagu Kurozumi · 2023
Read PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer by Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Yong Wha Moon, Masa-Aki Shibata, Sasagu Kurozumi (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10707354.txt.
Description
Researchers test in 2023 whether blocking a cell protein can deepen the effect of PARP drugs in breast and ovarian cancers with BRCA faults. PARP drugs exploit those faults to kill cancer cells, yet most tumors learn to resist. A second lethal partner could delay that escape.
The partner, PSPC1, is a speck protein inside the cell nucleus. Silencing it with a small RNA plus the drug olaparib kills mutant cells far better than either alone. Mouse tumors shrink more on the pair as well. The drug alone wakes repair signals, while the pair shuts them down and piles up DNA breaks. Cells then slip past a checkpoint with damage in tow, a path to death.
Catalog record
| CREATOR | Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Yong Wha Moon, Masa-Aki Shibata, Sasagu Kurozumi |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |